Skip to Main Content (Press Enter)

Logo UNICATT
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Persone
  • Pubblicazioni
  • Attività
  • Competenze

UNI-FIND
Logo UNICATT

|

UNI-FIND

unicatt.it
  • ×
  • Home
  • Corsi
  • Insegnamenti
  • Persone
  • Pubblicazioni
  • Attività
  • Competenze
  1. Pubblicazioni

Morbidity after pelvic exenteration for gynecological malignancies : A retrospective multicentric study of 230 patients

Articolo
Data di Pubblicazione:
2014
Citazione:
Chiantera, V., Rossi, M., De Iaco, P., Koehler, C., Marnitz, S., Fagotti, A., Fanfani, F., Parazzini, F., Schiavina, R., Scambia, G., Schneider, A., Vercellino, G. F., Morbidity after pelvic exenteration for gynecological malignancies : A retrospective multicentric study of 230 patients, <>, 2014; 24 (1): 156-164. [doi:10.1097/IGC.0000000000000011] [https://hdl.handle.net/10807/219575]
Abstract:
Objective: Our study purposewas to evaluatemorbidity and postoperative mortality in patients who underwent pelvic exenteration (PE) for primary or recurrent gynecological malignancies. Methods: We identified 230 patients who underwent PE, referred to the gynecological oncology units of 4 institutions: Charitè University in Berlin, Friedrich-Schiller University in Jena, S. Orsola-Malpighi University in Bologna, and Catholic University in Rome and in Campobasso. Results: The median age was 55 years. The tumor site was the cervix in 177 patients, the endometrium in 28 patients, the vulva in 16 patients, and the vagina in 9 patients. Sixty-eight anterior, 31 posterior, and 131 total PEs were performed in 116 women together with hysterectomy. A total of 82.6% of the patients required blood transfusion. The mean operative time was 446 (95-970) minutes, and the median hospitalization was 24 (7-210) days. We noted a major complication rate of 21.3% (n = 49). We registered 7 erioperative deaths (3%) calculated within 30 days. The operation was performed within clear margins in 166 patients (72.2%). The overall mortality rate depending on tumor site at the end of the study was 75%for vulvar cancer, 57.6%for cervical cancer, 55.6%for vaginal cancer, and 53.6% for endometrial cancer. Conclusions: Although an important effort for surgeons and for patients, PE remains a therapeutic option with an acceptable complication rate and postoperative mortality. A strict selection of patients is mandatory to reach adequate surgical and oncologic outcomes. © 2013 by IGCS and ESGO.
Tipologia CRIS:
Articolo in rivista, Nota a sentenza
Keywords:
Gynecological malignancies; Morbidity; Mortality; Pelvic exenteration
Elenco autori:
Chiantera, V.; Rossi, Marco; De Iaco, P.; Koehler, C.; Marnitz, S.; Fagotti, Anna; Fanfani, Francesco; Parazzini, F.; Schiavina, R.; Scambia, Giovanni; Schneider, A.; Vercellino, G. F.
Link alla scheda completa:
https://publicatt.unicatt.it/handle/10807/219575
Pubblicato in:
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
Journal
  • Aree Di Ricerca

Aree Di Ricerca

Settori (2)


LS7_7 - Surgery - (2011)

Settore MED/40 - GINECOLOGIA E OSTETRICIA
  • Utilizzo dei cookie

Realizzato con VIVO | Designed by Cineca | 26.5.0.0